Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures

NCT07219407 is registered in ClinicalTrials.gov with Rapport Therapeutics Inc. as lead sponsor.

NCT NCT07219407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
Lead sponsor
Rapport Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2025
Completion date
February 3, 2028
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, focal epilepsy, focal onset seizure, focal seizure, refractory focal epilepsy, seizure